(MedPage Today) — Oral semaglutide (Rybelsus) protected against heart failure events in type 2 diabetes patients with a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both, according to findings…
Source link : https://www.medpagetoday.com/cardiology/chf/119701
Author :
Publish date : 2026-02-02 21:48:00
Copyright for syndicated content belongs to the linked Source.
